🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Multimodal Imaging and Digital Pathology for Prostate Cancer Prediction

Recruitingn/aAges 40 Years - 90 YearsMaleGuangxi Medical University
NCT07614256 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a multicenter observational study. A deep learning model integrated with multimodal imaging and digital pathology spatial registration is built based on preoperative multiparametric magnetic resonance imaging, transrectal ultrasound and postoperative digital pathological whole slide images. The study is designed to achieve accurate prediction of clinically significant prostate cancer and non-invasive risk stratification. Unnecessary prostate biopsy and overdiagnosis can be reduced to support the optimization of clinical diagnosis and treatment strategies.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Subjects who are scheduled to undergo or have undergone prostate biopsy or radical prostatectomy. 2. Subjects who have completed standard-of-care preoperative multiparametric MRI (mpMRI) and transrectal ultrasound (TRUS) examinations. 3. Subjects with complete pathological diagnosis results available. 4. Age between 40 and 90 years. 5. Able and willing to provide written informed consent (for prospective cohort participants only). Exclusion Criteria: 1. Prior history of pelvic radiation therapy or radical prostatectomy. 2. Incomplete or poor-quality mpMRI or TRUS images (e.g., motion artifacts, insufficient sequences). 3. Concurrent other primary malignant tumors. 4. Severe systemic diseases that may affect the evaluation of the prostate. 5. Subjects with incomplete clinical or pathological data. 6. Contraindications to MRI examination (e.g., incompatible metallic implants, severe claustrophobia).
💊

What it tests

  • No Intervention: Observational Cohort
📍

Where

1 site
Liuzhou People's Hospital Affiliated to Guangxi Medical University
Liuzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy